LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Aktien・Becton Dickinson and Co

Becton Dickinson and Co

Geschlossen

BrancheGesundheitswesen

149 -2.54

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

146.03

Max

154.57

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.3B 382M
Verkäufe	-639M 5.3B
KGV Branchendurchschnitt	24.385 49.8
EPS	2.91
Dividendenrendite	2.79
Gewinnspanne	7.273
Angestellte	70,000
EBITDA	-86M 1.2B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+17.83% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	2.79% 2.25%
Nächstes Ergebnis	6. Aug. 2026
Nächste Dividendenausschüttung	30. Juni 2026
Nächstes Ex-Dividendendatum	9. Juni 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-16B 42B
Vorheriger Eröffnungskurs	151.54
Vorheriger Schlusskurs	149

Nachrichtenstimmung

By Acuity

26%

74%

75 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

167 / 206.99 Unterstützung & Widerstand

Becton Dickinson and Co Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Becton Dickinson and Co Prognose

Kursziel

By TipRanks

17.83% Vorteil

12-Monats-Prognose

Durchschnitt 180.58 USD 17.83%

Hoch 221 USD

Tief 157 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Becton Dickinson and Co – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Becton Dickinson and Co – Dist abgegeben haben.

Technischer Score

By Trading Central

167 / 206.99Unterstützung & Widerstand

Bearish events outweigh bullish events.

There is one bearish event.

Stimmung

By Acuity

75 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.